APA
BBIO icon

American Portfolios Advisors’s BridgeBio Pharma BBIO Stock Holding History

American Portfolios Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-32
Closed -$2.28K – 3275
2020
Q4 		$2.28K Buy
+32
New +$1.54K ﹤0.01% 2670

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Portfolios Advisors's BBIO Position: Q1 2021 in Review

American Portfolios Advisors sold out of BridgeBio Pharma (BBIO) in Q1 2021, closing a stake of 32 shares — an estimated $2.28K sold.

American Portfolios Advisors first reported a position in BBIO in Q4 2020 and held it in 1 quarter. The position peaked at $2.28K in Q4 2020. 198 funds tracked by Wall St. Rank hold BBIO as of Q1 2021.

  • American Portfolios Advisors reported no remaining BridgeBio Pharma position as of Q1 2021 after selling out during the quarter.
  • American Portfolios Advisors sold 32 BridgeBio Pharma shares in Q1 2021, an estimated $2.28K.
  • American Portfolios Advisors first reported a position in BridgeBio Pharma in Q4 2020 and held it in 1 quarter.
  • American Portfolios Advisors's BridgeBio Pharma position peaked at $2.28K in Q4 2020.
  • 198 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2021.

Based on American Portfolios Advisors's 13F filing for Q1 2021, filed 22 Mar 2023.